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Imidogen Linkers  
1	 3	
4	 8	
Erlotinib/Molecule 1/Molecule 27 
101.469534 nM 0.000054 nM  0.010398 nM 





Side Effect Value Probability 
Carcinogenicity (binary) - 0.9286 
Carcinogenicity (trinary) Non-required 0.5393 
Eye corrosion - 0.9897 
Eye irritation - 0.9683 
Ames mutagenesis - 0.57 
Human either-a-go-go inhibition + 0.6978 
micronuclear + 0.79 
Hepatotoxicity + 0.725 
Acute Oral Toxicity (c) III 0.6971 
Estrogen receptor binding + 0.8023 
Androgen receptor binding + 0.8696 
Thyroid receptor binding + 0.836 
Glucocorticoid receptor binding + 0.8971 
Aromatase binding + 0.8686 
PPAR gamma + 0.7436 
Honey bee toxicity - 0.6799 
Biodegradation - 0.75 
crustacea aquatic toxicity - 0.54 
Fish aquatic toxicity - 0.5407 
Data	retrieved	from	AdmetSar	
Side Effect Value Probability 
Carcinogenicity (binary) - 0.7714 
Carcinogenicity (trinary) Non-required 0.6508 
Eye corrosion - 0.9844 
Eye irritation - 0.9794 
Ames mutagenesis - 0.67 
Human either-a-go-go inhibition + 0.7917 
micronuclear + 0.76 
Hepatotoxicity - 0.5 
Acute Oral Toxicity (c) III 0.6025 
Estrogen receptor binding + 0.6001 
Androgen receptor binding + 0.6923 
Thyroid receptor binding + 0.5514 
Glucocorticoid receptor binding - 0.4772 
Aromatase binding + 0.6793 
PPAR gamma - 0.5306 
Honey bee toxicity - 0.6533 
Biodegradation - 0.85 
crustacea aquatic toxicity + 0.56 
Fish aquatic toxicity + 0.8465 
Molecule 1  
Data	retrieved	from	AdmetSar	
Molecule 27 
Side Effect Value Probability 
Carcinogenicity (binary) - 0.7571 
Carcinogenicity (trinary) Non-required 0.6396 
Eye corrosion - 0.9849 
Eye irritation - 0.9639 
Ames mutagenesis - 0.68 
Human either-a-go-go inhibition - 0.5857 
micronuclear + 0.78 
Hepatotoxicity - 0.55 
Acute Oral Toxicity (c) III 0.5846 
Estrogen receptor binding + 0.6639 
Androgen receptor binding + 0.6609 
Thyroid receptor binding + 0.6069 
Glucocorticoid receptor binding + 0.5453 
Aromatase binding + 0.594 
PPAR gamma + 0.6308 
Honey bee toxicity - 0.6845 
Biodegradation - 0.875 
crustacea aquatic toxicity + 0.6495 
Fish aquatic toxicity + 0.9055 
Data	retrieved	by	AdmetSar	
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